Greenfield-based Elanco Animal Health has received licensing approval from the U.S. Department of Agriculture for a swine vaccine. The Eli Lilly and Co. (NYSE: LLY) division says Prevacent reduces porcine reproductive and respiratory syndrome, a disease it estimates costs the industry between $560 million and $660 million per year.
The vaccine can be used in piglets two weeks or older. PRRS first emerged in the late-1980s. Elanco North America Food Animal Business Senior Director Chris Chavis says "PRRS has grown to be a costly and challenging disease that is difficult to control at the local, regional and national levels. We are eager to bring producers a new product to tackle this devastating disease." The vaccine, Chavis says, has been demonstrated to work for 26 weeks.
You can connect to more about the licensing announcement by clicking here.